| 摘要 |
FIELD: biotechnology, immunology. ^ SUBSTANCE: patient mononuclear cells are cultivated in presence of antigen selected from group containing myelin protein, collagen proteins, allergen, allogenic cells. Antigen-reactive blast T-cells are separated by using gradient centrifugation. Vaccine of present invention makes it possible to treat immunological disorders for 10-12 days. ^ EFFECT: new T-cell vaccine for treatment of immunological disorders associated with antigen presence. ^ 5 cl |
